PoC clinical study of ZPL-3893787 on pruritus and inflammation in atopic dermatitis

Ziarco Pharma Limited（坎特伯雷，肯特）正在开发ZPL-3893787，这是一种新型口服治疗与慢性瘙痒（CP）相关的瘙痒和炎症的药物，CP定义为刺激抓挠的不良状况，持续至少6周。它影响所有年龄段，从婴儿到老年人。CP可能导致睡眠障碍/缺乏，情绪变化和患者其他疾病的普遍增加。迄今为止，已在两个不同国家的50多名健康成人志愿者中对ZPL-3893787进行了研究。来自英国政府技术战略委员会的财政帮助将允许Ziarco测试ZPL-3893787用于缓解特应性皮炎（湿疹）患者的瘙痒和炎症。瘙痒和炎症存在于许多疾病中，如果证明成功，ZPL-389可能有机会治疗全球数百万患者，从年轻人到老年人。

Ziarco Pharma Limited, of Canterbury, Kent is developing ZPL-3893787, a novel oral treatment for the itch and inflammation associated with chronic pruritus (CP) - defined as an undesirable condition that stimulates scratching, persisting for at least 6 weeks. It affects all ages, from young infants through to the elderly. CP can result in disturbed/lack of sleep, mood changes and a general increase in other illnesses for sufferers. ZPL-3893787 has been studied in over 50 healthly adult volunteers so far in two different countries. Financial help from the UK Government's Technology Strategy Board will allow Ziarco to test ZPL-3893787 for relieving itch and inflammation in atopic dermatitis (ezcema) patients. Itch and inflammation are present in many diseases, and if proved successful, ZPL-389 may have the chance to treat millions of patients worldwide, from the young through to the elderly.